Communication Solutions for Patients
Several incapacitating neurological and medical conditions also result in an inability to adequately communicate, such as amyotrophic lateral sclerosis (Lou Gehrig’s disease) or following a stroke. The same is true for intensive care patients who are intubated and cannot speak. Fortunately, because eye movements remain largely intact in most neurological and medical conditions, communication with individuals is still possible. However, although possible, communication using eye movements can be a very slow and inefficient process when using current paper-based methods. This is why, at Innodem Neurosciences, we have developed the Pigio™ mobile application for communication. We believe that Pigio™, an intuitive, easy-to-use, and affordable mobile solution, will not only significantly improve the communication speed but also the quality of life of patients and caregivers alike. Pigio™ makes use of Innodem’s proprietary eye-tracking technology to interact with the user. Patients are able to control a cursor on the screen using only their eye movements. This allows them to rapidly communicate with others by selecting pre-defined sentences and words that are displayed on the screen.
Communication Solutions for Healthcare Professionals and Institutions
Healthcare professionals and the institutions that they work for, seek to improve the quality of care that they dispense to their patients in a cost-effective way. Nurses, neurologists, occupational therapists, and speech-language pathologists can all benefit from using Innodem Neurosciences’ Professional application. Hospitals and Private Clinics can therefore improve the quality of care that is dispensed.
More Than a Communication Platform:
Media & Entertainment to Enhance Patient Care
In addition to the core communication application, Pigio™ users will be able to access various media and entertainment applications. Currently, we support Netflix and YouTube, and we plan to continuously add new applications with subsequent updated versions of Pigio™.
YouTube is not affiliated with Innodem Neurosciences or the information contained on this website
Mobile Gaze-Tracking Software Technology
As stated above, current methods to communicate with paralyzed and intubated patients are time-consuming and can be frustrating, both for the patient and healthcare professional. Healthcare vendors have seized the opportunity to develop sophisticated, proprietary, technological hardware and software solutions to fill this void. Unfortunately, these solutions have had limited market penetration because of their high costs. We believe that an easy-to-use and affordable software application that can be downloaded to your smartphone or tablet is what patients and healthcare professionals require. To date, the major technological hurdle to this solution has been the development of an eye-tracking software capable of functioning with standard mobile device cameras. At Innodem Neurociences, we have successfully a patent-pending mobile gaze-tracking technology does not require any specialized hardware and is capable of working with almost any off-the-shelf mobile device. This new and innovative technology is at the core of pigio’s intuitive user interface, that has been designed to improve both patient communication abilities and healthcare quality.
AI Diagnostics & Predictability
As Pigio™ grows its user base, so too will our capacity to establish correlations between usage and various neurological diseases. Through a cloud-based AI core, we have made it possible to “learn” from end-users anonymously to better associate various neurological diseases to specific eye movement “signatures”. With this architecture, our goal is to support health professionals with improved diagnostics. Pharmaceutical companies involved in the development of new drugs realize that identifying the right patients for a clinical trial is pivotal. Innodem Neurosciences is developing the software technology to further optimize this fundamental process.
Innodem Neurosciences was founded by Dr. Etienne de Villers-Sidani in 2016. As a neurologist, he cares for paralyzed or intubated individuals that cannot communicate except through the movement of their eyes. He found the standard of care, a printed letter board, to be far too slow and impractical to efficiently communicate with patients. Furthermore, although proprietary hardware solutions were available on the market, they were rarely used by patients and clinicians, likely because of their high costs. He imagined a more intuitive, mobile, user-friendly, and affordable solution; one that would harness the camera embedded in every day mobile devices. Many patients and healthcare professionals today already own a smartphone or electronic tablet. For the past two years, he has been working with a team of software engineers, colleagues and with patients to develop eye tracking software technology. In 2018, his functional prototype was validated by angel financing. Innodem Neurosciences aims to become the global standard of care to improve the overall quality of care and quality of life of individuals struggling to communicate. Furthermore, Innodem Neurosciences is building state of the art diagnostic application, which will not only aid healthcare professionals but will also aid pharmaceutical industry.
Dr. Etienne de Villers Sidani
MD CM, FRCP (C)
Founder, CEO & CMO
Etienne is a neurologist, Associate Professor at McGill University and researcher at Montreal Neurological Institute and Hospital and member of the Center for Research on Brain, Language and Music (CRBLM). He is the main Founder, Chief Executive & Medical Officer of Innodem Neurosciences.
Alexandre holds a Master of Science in Brain-Computer Interfaces and is responsible for all technological research and development at Innodem Neurosciences. He is also a founding member.
B.Sc. (erg.), M.Ps.
Manager - Patient Tests
Delphine works as an occupational therapist at the The Centre Hospitalier de l’Université de Montréal. At Innodem, Delphine helps design and administer tests with patients and clients.
Chief Strategy Officer
Marc Reeves is a serial technology entrepreneur and a founding member of Innodem Neurosciences. He is Chief Strategy Officer and co-leads all corporate and business development activities including the various rounds of financing.
VP - Neuroscience Research
Patrice Voss is a Research Associate at the Montreal Neurological Institute and holds a Bachelor’s Degree in Psychology and a PhD in Cognitive Neuroscience from Université de Montréal. He leads all research at Innodem Neurosciences.
M.Fin., B.A. & B.Sc.
Director - Neuroscience Research
Francis holds a Masters of Management in Finance and a Bachelor’s Degree (Major in Cognitive Neurosciences) from McGill University. He oversees all day to day activities at Innodem Neurosciences.
Software Engineer & CTO
Yves is a founding member of Innodem Neurosciences and leads all product development.